PharmaEngine Inc 2020 SR
The report highlights PharmaEngine's commitment to developing innovative cancer drugs, specifically the success of ONIVYDE®, which is approved in over 40 countries. In 2020, the company focused on new drug projects PEP06 and PEP07 while maintaining a Virtual Pharmaceutical Company business model to optimize R&D resources. The company achieved a Top 5% ranking in the Corporate Governance Appraisal for the fourth consecutive year. Environmental efforts resulted in an 11.3% reduction in per capita CO2 emissions. Social initiatives included health education seminars and volunteer activities with the China Andrew Charity Association.
Company: PharmaEngine Inc
Sector: Health Care
Country: Taiwan
Year: 2020
Type: SR
Pages: 76
PharmaEngine Inc
Sustainability Report
The report highlights PharmaEngine's commitment to developing innovative cancer drugs, specifically the success of ONIVYDE®, which is approved in over 40 countries. In 2020, the company focused on new drug projects PEP06 and PEP07 while maintaining a Virtual Pharmaceutical Company business model to optimize R&D resources. The company achieved a Top 5% ranking in the Corporate Governance Appraisal for the fourth consecutive year. Environmental efforts resulted in an 11.3% reduction in per capita CO2 emissions. Social initiatives included health education seminars and volunteer activities with the China Andrew Charity Association.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
May 5, 2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women in Management
Workplace Fatalities
Employees